相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pioglitazone and Bladder Cancer A population-based study of Taiwanese
Chin-Hsiao Tseng
DIABETES CARE (2012)
Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
Chia-Hsuin Chang et al.
HEPATOLOGY (2012)
Diabetes mellitus correlates with increased risk of pancreatic cancer: A population-based cohort study in Taiwan
Kuan-Fu Liao et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Assiamira Ferrara et al.
DIABETES CARE (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
Carlo Piccinni et al.
DIABETES CARE (2011)
The Association Between Malignancy and End-stage Renal Disease in Taiwan
Ji-An Liang et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Diabetes and Cancer: A Consensus Report
Edward Giovannucci et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring Colorectal Cancer Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce Future Rates
Brenda K. Edwards et al.
CANCER (2010)
Thiazolidinediones Inhibit Hepatocarcinogenesis in Hepatitis B Virus Transgenic Mice by Peroxisome Proliferator-Activated Receptor γ-Independent Regulation of Nucleophosmin
Andrea Galli et al.
HEPATOLOGY (2010)
Peroxisome Proliferator-Activated Receptor gamma Pathway Targeting in Carcinogenesis: Implications for Chemoprevention
Frank Ondrey
CLINICAL CANCER RESEARCH (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System
Maria E. Ramos-Nino et al.
BMC MEDICINE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
Diabetes, insulin, and risk of cancer
R. Schiel et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2006)
From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
JN Feige et al.
PROGRESS IN LIPID RESEARCH (2006)
Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)
Y Bren-Mattison et al.
ONCOGENE (2005)
Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
C Grommes et al.
LANCET ONCOLOGY (2004)
Does universal health insurance make health care unaffordable? Lessons from Taiwan
JFR Lu et al.
HEALTH AFFAIRS (2003)
Troglitazone and related compounds - Therapeutic potential beyond diabetes
T Fujiwara et al.
LIFE SCIENCES (2000)
Epidemiologic study of type 2 diabetes in Taiwan
CJ Chang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2000)
分享论文
